Aviva Ventures, Aviva plc's venture capital arm, has invested in Owlstone Medical Ltd, a medical diagnostics company developing a breathalyser that can detect diseases at a very early stage.
The company is currently developing tests for lung and colorectal cancer, two of the most common terminal cancer conditions worldwide. Aviva Ventures' investment takes Owlstone Medical's total funding to $23.5 million USD (£19.3 million GBP) since its spin out of Owlstone Inc in 2016. Aviva Ventures provides early stage investment to back entrepreneurs with high growth businesses and, over time, expects to have a portfolio of small investments in a number of companies which have significant...
Bill broadened to include insurable interest in cohabitants, group schemes and trusts
Thursday 4th October at The Hilton London Bankside
Early conversations about end-of-life care are crucial to ensure individuals living longer can make their own decisions, however right-to-die approaches vary all over the world
Group life, critical illness and income protection business bought from Munich Re